These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2137785)

  • 1. Immunogenicity of yeast-derived hepatitis B vaccine from two different producers.
    Dahl-Hansen E; Siebke JC; Frøland SS; Degré M
    Epidemiol Infect; 1990 Feb; 104(1):143-9. PubMed ID: 2137785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children.
    Milne A; Moyes CD; Allwood GK; Pearce NE; Krugman S
    N Z Med J; 1988 Feb; 101(840):67-9. PubMed ID: 2967940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study.
    Goh KT; Tan KL; Kong KH; Oon CJ; Chan SH
    Bull World Health Organ; 1992; 70(2):233-9. PubMed ID: 1600584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
    Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactogenicity and immunogenicity of a new recombinant yeast-derived hepatitis B vaccine.
    Scheiermann N; Gesemann KM; Paar D; Maurer C
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Nov; 269(3):411-21. PubMed ID: 2975448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines.
    Hammond GW; Parker J; Mimms L; Tate R; Sekla L; Minuk G
    Vaccine; 1991 Feb; 9(2):97-100. PubMed ID: 1829306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients.
    Jilg W; Schmidt M; Weinel B; Küttler T; Brass H; Bommer J; Müller R; Schulte B; Schwarzbeck A; Deinhardt F
    J Hepatol; 1986; 3(2):190-5. PubMed ID: 3794300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA.
    Zajac BA; West DJ; McAleer WJ; Scolnick EM
    J Infect; 1986 Jul; 13 Suppl A():39-45. PubMed ID: 2943814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of low doses of recombinant hepatitis B vaccine in young males.
    Tsakalakis C; Richardson SC; Roumeliotou-Karayannis A; Papaevangelou G
    Vaccine; 1988 Aug; 6(4):328-30. PubMed ID: 2973188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B vaccine boosters: further studies in children.
    Milne A; Waldon J; Moyes CD; Pearce NE
    N Z Med J; 1990 Nov; 103(901):539-41. PubMed ID: 2147053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a low dose recombinant DNA hepatitis B vaccine in healthy adults in Singapore.
    Guan R; Tay HH; Yap I; Smith R; Tan LH
    Asian Pac J Allergy Immunol; 1989 Dec; 7(2):85-8. PubMed ID: 2533866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular response and anti-HBs synthesis in vitro after vaccination with yeast-derived recombinant hepatitis vaccine.
    Degrassi A; Mariani E; Honorati MC; Roda P; Miniero R; Capelli M; Facchini A
    Vaccine; 1992; 10(9):617-22. PubMed ID: 1386954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the immunogenicity of reduced doses of two recombinant DNA hepatitis B vaccines in New Zealand children.
    Milne A; Brawner TA; Dumbill PC; Kawachi I; Pearce NE
    J Med Virol; 1989 Mar; 27(3):264-7. PubMed ID: 2524549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a purified hepatitis B virus vaccine prepared by using recombinant DNA technology.
    Zahradnik JM; Couch RB; Gerin JL
    J Infect Dis; 1987 May; 155(5):903-8. PubMed ID: 2951449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune response after hepatitis A vaccination in haemodialysis patients: comparison with hepatitis B vaccination.
    Kuramoto I; Fujiyama S; Matsushita K; Sato T
    J Gastroenterol Hepatol; 1994; 9(3):228-31. PubMed ID: 8054520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization against hepatitis B--what can we expect? Results of a survey of antibody response to immunization in persons 'at risk' of occupational exposure to hepatitis B.
    Westmoreland D; Player V; Heap DC; Hammond A
    Epidemiol Infect; 1990 Jun; 104(3):499-509. PubMed ID: 2140795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a recombinant yeast-derived hepatitis B vaccine (Engerix B) in children.
    Moyes C; Milne A
    N Z Med J; 1988 Apr; 101(843):162-4. PubMed ID: 2965799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunogenicity and harmlessness in the newborn of a vaccine (GenHevac B) containing the antigens S and pre-S2].
    Tron F; Soulié JC; Goudeau A; Devillier P; Saliou P
    Bull Soc Pathol Exot; 1991; 84(5 Pt 5):901-5. PubMed ID: 1840243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the immunogenicity of hepatitis B vaccine administered intradermally and intramuscularly.
    King JW; Taylor EM; Crow SD; White MC; Todd JR; Poe MB; Conrad SA; Gelder FB
    Rev Infect Dis; 1990; 12(6):1035-43. PubMed ID: 2148433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunogenicity and tolerance of a combined hepatitis A/B vaccine. Preliminary results with a candidate vaccine].
    Kallinowski B; Bock HL; Clemens R; Theilmann L
    Dtsch Med Wochenschr; 1995 Oct; 120(42):1426-9. PubMed ID: 7555671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.